The influence of many factors on the operation of the heart valve replacement surgery. For example, long-term placement of exogenous substances in the body, easy to cause postoperative inflammatory reaction, may face the risk of two surgery, which will undoubtedly bring more serious economic burden and more medical risks.

Swiss Xeltis medical instrument company recently released news, says it has independently developed the world's first bio absorbable heart valve. The valve can be absorbed by the porous matrix material composition, has the role of promoting the body tissue growth and natural healing, in the organization of the new valve gradually absorbed and digested. At present, the company has successfully completed the second heart valve of the feasibility studies, good data to make the investors for the heart.

Xeltis also plans to submit its application to the EU in 2018 to submit its CE mark of another pulmonary valve product, in order to obtain the right to promote and sell the product in the EU region.

According to Xeltis company officials, the company has the endogenous tissue repair technology (ETR), mainly based on the Nobel prize winner professor Lehn Jean-Marie professor of supramolecular chemistry research results. In essence, can be absorbed by the design and implantation of biological materials, as the body of the heart valve, blood vessels or tissues and play a role in the body of the corresponding tissue and function is perfect, these can be absorbed by the body to absorb biological materials.

The company has developed a new heart - blood vessel patch (patch cardio-vascular), can be implanted in the heart of a single ventricle in children undergoing cardiac malformations. The results showed that all patients had no postoperative complications, and there were no cases of surgical intervention for patients with cardiac dysfunction after one year.

Although the clinical needs of valve repair to the development of partial niche, Xeltis CEO Laurent Grandidier was still convinced that the company's efforts will become the other heart vascular membrane can absorb the cornerstone of development and the development of biological materials. At present, the company has a platform development technology, can carry out many of the development of valve materials for cardiovascular replacement, this technology platform has become the biggest highlight of the advantages of attracting investors.

In 2014, private equity firm LSP has to issue B series of private equity funds in the form of Xeltis company raised 27 million euros huge investment. Xeltis company's development objective is: to cost benefit analysis of the idea to seek profit steady growth, this business deployment and operation mode has been good for LSP and other wealth investors.

At present, Xeltis is actively preparing for the listing of its heart valve products, mainly for children with congenital heart disease of the heart malformation correction, hoping to get the relevant market access permits, the benefit of more patients.